# OnCo record paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025" ;
  schema:name "eNRGy: efficacy of zenocutuzumab in NRG1 fusion-positive cancer"@en ;
  schema:description "Zenocutuzumab, an antibody that grips HER2 and HER3 at once so the NRG1 growth signal cannot get through, shrank tumours in about three in ten patients whose cancers carried an NRG1 fusion, with responses lasting close to a year, and did best in pancreatic cancer. It became the first drug approved for a pancreatic cancer driver alteration."@en ;
  schema:url <https://onco.cc/key-papers/paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2405008>, <https://pubmed.ncbi.nlm.nih.gov/39908431/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2405008> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Schram AM, Goto K, Kim DW, et al." ;
  onco:cancers <https://onco.cc/cancers/kras-wild-type-pdac/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:drugs <https://onco.cc/drugs/zenocutuzumab/> ;
  onco:trials <https://onco.cc/trials/nct02912949/> ;
  onco:people <https://onco.cc/people/eileen-oreilly/>, <https://onco.cc/people/alexander-drilon/> ;
  onco:journals <https://onco.cc/journals/nejm/> .